AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer
用户z61zp6yUMKaw
3个月前
128
10
已完结
1. 系统已在2025-07-05 09:34:38对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.ygyno.2025.04.579
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0090825825008054
其他信息:
出版社: Elsevier BV
作者: Jung-Yun Lee; Sathana Boonyapipat; Guangwen Yuan; Hee Seung Kim; Jeong-Won Lee; Li Wang; Tao Wang; Danbo Wang; Desheng Yao; Hu Liu; Chih-Long Chang; Timur Turdeevich Andabekov; Xiang Zhang; Wei Wang; Yong Man Kim; Ivan Volodymyrovych Sinielnikov; Kai Wang; Yujuan Gao; Xiyan Mu; Lingying Wu
